Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression

Figures & data

Table 1. Individual patient data on malignant pleural mesothelioma.

No.	Age	Sex	Histology	Asbestos history	S.I.(pack/year)	Stage	Surgical history	TS	DPD	OPRT	TP	Initial treatment	Survival time(days)
1	70	F	Epithelioid mesothelioma	—	unknown	I	P/D	1	5	5	5	CBDCA+Pem	381^*
2	87	M	Biphasic mesothelioma	—	40	IV	—	4	1	4	1	Pem	72
3	66	M	Desmoplastic mesothelioma	unknown	unknown	IV	—	NA	NA	NA	NA	CBDCA+Pem	562^*
4	41	M	Mesothelioma, malignant	—	Never	NA	—	1	5	4	4	CBDCA+GEM	190
5	63	M	Mesothelioma, malignant	—	unknown	NA	—	3	1	2	1	BSC	23
6	71	M	Metothelioma, malignant	+	69	IV	—	1	5	5	1	CDDP+Pem	1492^*
7	60	M	Biphasic mesothelioma	+	30	III	EPP	3	4	2	1	CBDCA+Pem	591
8	63	M	Biphasic mesothelioma	—	80	IV	—	4	5	5	4	CDDP+Pem	80
9	73	M	Epithelioid mesothelioma	—	Never	III	EPP	1	5	5	1	CBDCA+Pem	960^*
10	66	M	Epithelioid mesothelioma	+	24	IV	—	2	4	3	3	CBDCA+Pem	928^*
11	68	M	Desmoplastic mesothelioma	unknown	Never	IV	—	1	1	5	1	CBDCA+Pem	485
12	66	M	Desmoplastic mesothelioma	—	22	III	—	1	1	5	2	CBDCA+Pem	177
13	68	M	Epithelioid mesothelioma	unknown	45	IV	—	2	4	4	5	BSC	33
14	78	M	Epithelioid mesothelioma	—	Never	I	—	1	4	5	5	CBDCA+Pem	318^*
15	83	M	Desmoplastic mesothelioma	—	20	III	—	1	4	5	3	CBDCA+Pem	262^*

Note.

* As of December 2014, alive at the time of evaluation.

Figure 1. Examples of immunohistochemical staining of MPM.

Table 2. Positive rates of TS, DPD, OPRT, and TP according to clinicopathological factors.

	TS		DPD		OPRT		TP
Parameter	High (n = 4)	Low (n = 10)	High (n = 10)	Low (n = 4)	High (n = 12)	Low (n = 2)	High (n = 5)	Low (n = 9)
Age (≤65 />65 years)	1/3	1/9	7/3	3/1	10/2	0/2	3/2	7/2
Gender (Male/female)	4/0	9/1	9/1	4/0	11/1	2/0	4/1	9/0
Histology (Epithelioid/Desmoplastic/Biphasic/unknown)	0/0/3/1	5/3/0/2	5/1/2/2	0/2/1/1	5/3/2/2	0/0/1/1	3/0/1/1	2/3/2/2
TS (High/Low)	—	—	2/8	2/2	2/10	2/0	1/4	3/6
DPD (Hight/Low)	2/2	8/2	—	—	9/3	1/1	5/0	5/4
OPRT (High/Low)	2/2	10/0	9/1	3/1	—	—	5/0	7/2
TP (High/Low)	1/3	4/6	5/5	0/4	5/7	0/2	—	—

Figure 2. Computed tomography shows S-1+CBDCA treatment course.

Figure 3. Mechanism of TS inhibitors (5-FU and Pemetrexed).